The USA has made 2 interesting cannabis moves recently:

1. the Whitehouse directed that cannabis be rescheduled from schedule 1 (no medical use) to 3 (has medical use).
2. congress (I think) also moved to close hemp-derived THC loopholes that have seen all kinds of gummies and drinks sold at gas stations.

On the cannabis front this was largely foreshadowed. Rescheduling is good for existing cannabis businesses because they can bill and pay tax more easily.

On the hemp-derived front, the extreme-limitation implied on per-serve potency would kill a lot of business. It has created a flurry of lobbying efforts to discuss more reasonable limits on serving potency and manufacturing standards. The whole kerfuffle might kill some operators while leaving the field open for whoever can adjust to moving-target regulations and stay in the good books - such as, perhaps, one of our own, Peak Processing.

@Strawman are any of our industry players: Bioxyne, Little Green Pharma or Peak Processing available to chat? It would be great to hear how these changes affect their business.

Especially interested in hearing from Peak Processing (formerly Althea Group) about the drinks market. Not sure if they have a handle on the limits enough to speak openly yet. But they are positioned well, with deals with major drink brands and an established and dominant business in THC-infused drinks in Canada. They have recently refreshed the organisation and leadership team to focus on the Peak Processing drinks business, so who knows, maybe he will be ready to chat.